sinc
first
recogn
case
human
infect
avian
influenza
viru
worldwid
spread
reemerg
highli
pathogen
influenza
viru
led
human
infect
case
case
die
http
wwwwhointinfluenza
morbid
rate
much
higher
season
influenza
viru
outbreak
viru
epidem
warn
sign
occurr
new
influenza
pandem
sustain
circul
virus
poultri
anim
pose
persist
threat
public
health
addit
recent
studi
influenza
viru
transmiss
prove
amino
acid
mutat
requir
make
viru
transmiss
among
ferret
anim
model
resembl
human
respons
influenza
viru
infect
consid
potenti
mutat
avian
influenza
viru
easili
transmit
highli
pathogen
human
time
take
measur
next
come
influenza
pandem
enter
host
cell
influenza
viru
first
massiv
replic
induc
acut
sever
immun
respons
lead
seriou
respiratori
injuri
consequ
acut
lung
injuri
ali
acut
respiratori
distress
syndrom
ard
present
due
limit
therapeut
strategi
influenza
viru
infect
ard
mortal
rate
human
infect
high
pathogen
remain
high
therefor
find
effect
prophylact
therapeut
agent
potenti
allevi
virusinduc
lung
injuri
great
import
reinvestig
exist
drug
econom
timesav
approach
satisfi
unmet
medic
need
safeti
pharmacolog
formul
potenti
toxic
shelv
drug
larg
establish
previou
studi
shown
angiotensin
ii
receptor
blocker
arb
losartan
could
effect
reduc
ali
induc
sarscov
recent
report
avian
influenza
viru
infect
disrupt
host
reninangiotensin
system
ra
mice
human
plasma
level
angiotensin
ii
markedli
elev
infect
patient
consist
found
administr
recombin
human
protein
effect
amelior
murin
ali
induc
viru
infect
dysregul
angiotensin
ii
level
highli
associ
diseas
hypertens
cardiac
figur
losartan
effect
amelior
ali
induc
avian
influenza
viru
infect
mice
surviv
rate
mice
receiv
losartan
vehicl
control
per
day
continu
day
intratrach
instil
viru
surviv
rate
data
collect
mice
per
group
b
wetdri
weight
ratio
indic
sever
lung
edema
mice
without
losartan
treatment
lung
tissu
obtain
day
viru
instil
data
mice
per
group
c
repres
lung
histopatholog
mice
day
viru
infect
follow
therapeut
treatment
losartan
lower
panel
compar
nontreat
group
upper
panel
origin
magnif
left
panel
follow
increas
magnif
right
panel
total
field
analyz
mice
group
bar
graph
stand
lung
injuri
score
left
number
infiltr
cell
infect
lung
tissu
right
data
present
rtqpcr
analysi
compon
viru
data
present
rel
express
level
mice
per
group
e
rtqpcr
analysi
express
rel
mous
lung
tissu
follow
therapeut
treatment
losartan
vehicl
control
data
mice
per
group
analyz
f
western
blot
analysi
ace
express
mous
lung
tissu
follow
losartan
treatment
intern
control
repres
blot
shown
left
pool
four
mice
lung
lysat
analyz
present
bar
graph
shown
middl
ace
right
data
present
mean
aceor
mice
group
diseas
two
class
drug
alreadi
develop
clinic
appli
maintain
normal
function
ra
first
class
ace
inhibitor
acei
inhibit
ace
cleav
angiotensin
gener
angiotensin
ii
second
class
angiotensin
ii
receptor
blocker
arb
block
interact
angiotensin
ii
type
receptor
suppress
downstream
immun
respons
thu
hypothes
drug
demonstr
therapeut
consequ
increas
protein
express
may
also
effect
treatment
infect
previou
studi
shown
arb
perform
better
acei
respiratori
disord
ard
induc
bacteri
infect
angiotensin
ii
synthes
altern
enzym
chymas
cathepsin
trypsin
thu
studi
focus
losartan
first
oral
activ
nonpeptid
select
arb
investig
therapeut
role
ali
induc
viru
test
potenti
therapeut
effect
losartan
ali
induc
live
viru
use
losartan
develop
dupont
merck
pharmaceut
co
code
potassium
salt
thyl
imidazol
molecular
mass
da
found
administr
losartan
dose
clinic
equival
human
significantli
improv
surviv
rate
virusinfect
mice
figur
sever
lung
injuri
determin
lung
histopatholog
wetdri
lung
weight
ratio
indic
lung
edema
mice
treat
losartan
show
allevi
lung
edema
improv
lung
histopatholog
demonstr
lower
lung
injuri
score
reduc
number
infiltr
leukocyt
figur
c
taken
togeth
result
suggest
losartan
convent
antihypertens
medic
promis
strategi
amelior
ali
improv
surviv
mice
infect
live
avian
influenza
viru
though
effect
treat
losartan
viral
load
lung
tissu
infect
mice
reduc
losartan
treatment
indic
losartan
may
influenc
viral
entri
replic
figur
sinc
bind
angiotensin
ii
promot
inflamm
vascular
permeabl
lung
tissu
least
partial
account
ali
induc
viru
suppos
effect
losartan
may
result
prevent
excess
downstream
inflammatori
respons
agreement
one
primari
contributor
cytokin
downstream
also
significantli
downregul
losartantr
group
figur
furthermor
remark
recoveri
express
downregul
ace
lung
tissu
losartantr
mice
also
observ
h
viru
infect
figur
data
support
notion
mechan
action
losartan
context
influenza
viru
infect
mediat
via
ra
pathway
dr
david
fedson
recent
call
use
statin
arb
acei
next
influenza
pandem
previou
populationbas
studi
clearli
demonstr
arb
inpati
applic
sever
pneumonia
could
significantli
reduc
mortal
rate
hospit
provid
experiment
evid
losartan
perhap
arb
consid
candid
therapi
clinic
treatment
patient
herein
random
clinic
trial
arb
treatment
ard
inde
need
